We Offer Worldwide Shipping
Login Wishlist

Bis(3-ethyl-5-methyl-4-maleimidophenyl)methane

$96

  • Brand : BIOFRON

  • Catalogue Number : BN-O1106

  • Specification : 98%(HPLC)

  • CAS number : 105391-33-1

  • Formula : C27H26N2O4

  • Molecular Weight : 442.5

  • PUBCHEM ID : 10950302

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1106

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

442.5

Appearance

Botanical Source

Structure Type

Category

SMILES

CCC1=C(C(=CC(=C1)CC2=CC(=C(C(=C2)C)N3C(=O)C=CC3=O)CC)C)N4C(=O)C=CC4=O

Synonyms

1,1'-[Methylenebis(2-ethyl-6-methyl-4,1-phenylene)]bis(1H-pyrrole-2,5-dione)/Bis(3-ethyl-5-Methyl-4-MaleiMidophenyl)Methane/1H-Pyrrole-2,5-dione, 1,1'-[methylenebis(2-ethyl-6-methyl-4,1-phenylene)]bis-/1-[4-[[4-(2,5-dioxopyrrol-1-yl)-3-ethyl-5-methylphenyl]methyl]-2-ethyl-6-methylphenyl]pyrrole-2,5-dione

IUPAC Name

1-[4-[[4-(2,5-dioxopyrrol-1-yl)-3-ethyl-5-methylphenyl]methyl]-2-ethyl-6-methylphenyl]pyrrole-2,5-dione

Density

1.3±0.1 g/cm3

Solubility

Flash Point

266.8±23.9 °C

Boiling Point

618.7±55.0 °C at 760 mmHg

Melting Point

165ºC

InChl

InChl Key

YNSSPVZNXLACMW-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:105391-33-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31851691

Abstract

Companies tend to publish financial reports in order to articulate strategies, disclose key performance measurements as well as summarise the complex relationships with external stakeholders as a result of their business activities. Therefore, any major changes to business models or key relationships will be naturally reflected within these documents, albeit in an unstructured manner. In this research, we automatically scan through a large and rich database, containing over 400,000 reports of companies in Japan, in order to generate structured sets of data that capture the essential features, interactions and resulting relationships among these firms. In doing so, we generate a citation type network where we empirically observe that node creation, annihilation and link rewiring to be the dominant processes driving its structure and formation. These processes prompt the network to rapidly evolve, with over a quarter of the interactions between firms being altered within every single calendar year. In order to confirm our empirical observations and to highlight and replicate the essential dynamics of each of the three processes separately, we borrow inspiration from ecosystems and evolutionary theory. Specifically, we construct a network evolutionary model where we adapt and incorporate the concept of fitness within our numerical analysis to be a proxy real measure of a company’s importance. By making use of parameters estimated from the real data, we find that our model reliably replicates degree distributions and motif formations of the citation network, and therefore reproducing both macro as well as micro, local level, structural features. This is done with the exception of the real frequency of bidirectional links, which are primarily formed as a result of an entirely separate and distinct process, namely the equity investments from one company into another.

Title

Dynamics of essential interaction between firms on financial reports

Author

Hayato Goto, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing - original draft,1,2,* Eduardo Viegas, Conceptualization, Formal analysis, Investigation, Methodology, Validation, Writing - original draft,1 Hideki Takayasu, Investigation, Methodology, Supervision, Validation, Writing - review & editing,2,3 Misako Takayasu, Funding acquisition, Investigation, Supervision, Validation, Writing - review & editing,2 and Henrik Jeldtoft Jensen, Investigation, Project administration, Supervision, Validation, Writing - review & editing1,2 Yohsuke Murase, Editor

Publish date

2019

PMID

24275849

Abstract

CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996-2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register. An association between malformations and maternal use of anticonvulsants and notably valproic acid is well known from the literature and also demonstrated in the present study. Some other associations between drug exposure and outcome were found.

KEYWORDS

CNS active drugs, opioids, sedatives, hypnotics, antidepressants, psychostimulants, congenital malformations, neonatal morbidity

Title

The Use of Central Nervous System Active Drugs During Pregnancy

Author

Bengt Kallen,1,* Natalia Borg,2 and Margareta Reis3

Publish date

2013 Oct;

PMID

20777727

Title

OCCUPATIONAL DISEASES OF THE SKIN

Author

John C. Bridge

Publish date

1933 Aug 19;


Description :

Empty ...